Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB's liver cancer drug Rivoceranib can be addressed through voluntary corrective actions, easing market concerns over the treatment.
HLBLife ScienceR&D, the research and development subsidiary of HLB, a prominent Korean life sciences conglomerate, has been selected for its fifth government-backed research project this year, according to the firm.
The studio reinforces HLB's commitment to delivering exceptional client experiences in the Pacific Northwest... About HLB Lighting DesignFounded in 1968, HLB Lighting Design is the largest independent architectural lighting design firm in the world.